Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar;16(3):35.
doi: 10.1007/s11892-016-0724-8.

MicroRNAs in Diabetic Nephropathy: From Biomarkers to Therapy

Kate Simpson  1 , Alexa Wonnacott  1 , Donald J Fraser  1 , Timothy Bowen  2
Affiliations
Review

MicroRNAs in Diabetic Nephropathy: From Biomarkers to Therapy

Kate Simpson et al. Curr Diab Rep. 2016 Mar.

Abstract

Recent estimates suggest that 1 in 12 of the global population suffers from diabetes mellitus. Approximately 40 % of those affected will go on to develop diabetes-related chronic kidney disease or diabetic nephropathy (DN). DN is a major cause of disability and premature death. Existing tests for prognostic purposes are limited and can be invasive, and interventions to delay progression are challenging. MicroRNAs (miRNAs) are a recently described class of molecular regulators found ubiquitously in human tissues and bodily fluids, where they are highly stable. Alterations in miRNA expression profiles have been observed in numerous diseases. Blood and tissue miRNAs are already established cancer biomarkers, and cardiovascular, metabolic and immune disease miRNA biomarkers are under development. Urinary miRNAs represent a potential novel source of non-invasive biomarkers for kidney diseases, including DN. In addition, recent data suggest that miRNAs may have therapeutic applications. Here, we review the utility of miRNAs as biomarkers for the early detection and progression of DN, assess emerging data on miRNAs implicated in DN pathology and discuss how the data from both fields may contribute to the development of novel therapeutic agents.

Keywords: Biomarker; Diabetic nephropathy; Fibrosis; MicroRNA; Non-coding RNA; Therapeutics.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
MicroRNA biogenesis and repression of gene expression
See this image and copyright information in PMC

References

    1. World Health Organisation . Global status on noncommunicable diseases. Geneva: World Health Organisation; 2014.
    1. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260–72. doi: 10.1016/S0140-6736(13)60687-X. - DOI - PubMed
    1. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med. 1989;321(16):1074–9. doi: 10.1056/NEJM198910193211603. - DOI - PubMed
    1. Regele F, Jelencsics K, Shiffman D, Pare G, McQueen MJ, Mann JF, et al. Genome-wide studies to identify risk factors for kidney disease with a focus on patients with diabetes. Nephrol Dial Transplant. 2015;30 Suppl 4:iv26–34. doi: 10.1093/ndt/gfv087. - DOI - PubMed
    1. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med. 1991;325(12):836–42. doi: 10.1056/NEJM199109193251202. - DOI - PubMed

Publication types

LinkOut - more resources